Herpes zoster secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Aysha Aslam (talk | contribs) |
|||
| Line 8: | Line 8: | ||
If the patient is immunocompetent with: | If the patient is immunocompetent with: | ||
*Localized herpes zoster | *'''Localized herpes zoster''': then standard precautions should be followed and lesions should be completely covered. | ||
*Disseminated herpes zoster | *'''Disseminated herpes zoster'''': defined as appearance of lesions outside the primary or adjacent dermatomes, then standard precautions plus airborne and contact precautions should be followed until lesions are dry and crusted. | ||
If the patient is immunocompromised with: | If the patient is immunocompromised with: | ||
*Localized herpes zoster | *'''Localized herpes zoster''': then standard precautions plus airborne and contact precautions should be followed until disseminated infection is ruled out. Then standard precautions should be followed until lesions are dry and crusted. | ||
*Disseminated herpes zoster | *'''Disseminated herpes zoster''': then standard precautions plus airborne and contact precautions should be followed until lesions are dry and crusted. | ||
====Management of Healthcare Personnel==== | ====Management of Healthcare Personnel==== | ||
Revision as of 16:20, 24 October 2016
|
Herpes zoster Microchapters |
|
Diagnosis |
|---|
|
History and Symptoms |
|
Treatment |
|
Case Studies |
|
Herpes zoster secondary prevention On the Web |
|
American Roentgen Ray Society Images of Herpes zoster secondary prevention |
|
Risk calculators and risk factors for Herpes zoster secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; L. Katie Morrison, MD; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Secondary Prevention
Management of Patients with Herpes Zoster
Infection-control measures depend on whether the patient with herpes zoster is immunocompetent or immunocompromised and on whether the rash is localized or disseminated. In all cases, standard infection-control precautions should be followed.
If the patient is immunocompetent with:
- Localized herpes zoster: then standard precautions should be followed and lesions should be completely covered.
- Disseminated herpes zoster': defined as appearance of lesions outside the primary or adjacent dermatomes, then standard precautions plus airborne and contact precautions should be followed until lesions are dry and crusted.
If the patient is immunocompromised with:
- Localized herpes zoster: then standard precautions plus airborne and contact precautions should be followed until disseminated infection is ruled out. Then standard precautions should be followed until lesions are dry and crusted.
- Disseminated herpes zoster: then standard precautions plus airborne and contact precautions should be followed until lesions are dry and crusted.
Management of Healthcare Personnel
The following steps should be taken when healthcare personnel (HCP) are exposed to someone with varicella or herpes zoster:
- HCP who have received 2 doses of varicella vaccine should be monitored daily during postexposure days 8–21 for fever, skin lesions, and systemic symptoms suggestive of varicella. HCP can be monitored directly by employee health program or infection control practitioners or instructed to report fever, headache, or other constitutional symptoms and any atypical skin lesions immediately. If symptoms occur, the HCP should be immediately removed from patient care areas and receive antiviral medication. Healthcare personnel with varicella and disseminated herpes zoster should be excluded from work until all lesions have dried and crusted or, in the absence of vesicular lesions, until no new lesions have appeared for 24 hours.
- HCP who have received 1 dose of varicella vaccine should receive the second dose at any interval after exposure to someone with rash (provided 4 weeks have elapsed after the first dose). After vaccination, management is the same as that of HCP who have received 2 doses of varicella vaccine.
- Unvaccinated VZV-susceptible HCP are potentially infective from days 8 to 21 after exposure and should be furloughed or temporarily reassigned to locations remote from patient-care areas during this period. Exposed HCP without evidence of immunity should receive postexposure vaccination as soon as possible. Vaccination within 3–5 days of exposure to rash may modify the disease if infection occurred. Vaccination 6 or more days after exposure is still indicated because it induces protection against subsequent exposures (if the current exposure did not cause infection). For unvaccinated VZV-susceptible HCP at risk for severe disease and for whom varicella vaccination is contraindicated (e.g., pregnant HCP), varicella-zoster immune globulin after exposure is recommended.